2. Signaling Pathways
  3. Anti-infection
  4. RSV

RSV

Respiratory syncytial virus

RSV

Related Products

PDF 0.17 MB

RSV (Respiratory syncytial virus) is a leading cause of acute respiratory infections. RSV can exploit host immunity and cause a strong inflammatory response that leads to lung damage and virus dissemination. There is a single RSV serotype with two major antigenic subgroups, A and B.

RSV is a non-segmented negative-sense single-stranded enveloped RNA virus that belongs to the family of Paramyxoviridae, genus Pneumovirus, subfamily Pneumovirinae. Its 10 genes encode 11 proteins since two overlapping open reading frames in the M2 mRNA yield two distinct matrix proteins, M2-1 and M2-2. The viral envelope contains three proteins, the G glycoprotein, the fusion (F) glycoprotein, and the small hydrophobic (SH) protein. The RSV virus comprises five other structural proteins, the large (L) protein, nucleocapsid (N), phosphoprotein (P), matrix (M), and M2-1, and two non-structural proteins (NS1 and NS2).

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-11097
    TMC353121
    		Inhibitor ≥98.0%
    TMC353121 is a potent respiratory syncytial virus (RSV) fusion inhibitor with pEC50 of 9.9.
    TMC353121
  • HY-12983A
    Lumicitabine
    		Inhibitor 99.34%
    Lumicitabine (ALS-008176) is an inhibitor of the respiratory syncytial virus (RSV) polymerase.
    Lumicitabine
  • HY-145119AS
    Mindeudesivir hydrobromide
    		Inhibitor 99.46%
    Mindeudesivir (JT001; VV116; GS-621763-d1) hydrobromide is a deuterated version of Remdesivir (HY-104077), a highly orally active nucleoside antiviral against SARS-CoV-2 and respiratory syncytial virus (RSV). Mindeudesivir hydrobromide retains the antiviral activity of Remdesivir against COVID-19, and is the first domestically produced deuterium targeting the COVID-19.
    Mindeudesivir hydrobromide
  • HY-12993
    RSV604
    		Inhibitor 99.92%
    RSV604 (A-60444) is an inhibitor of respiratory syncytial virus (RSV) replication. RSV604 targets the nucleocapsid protein, with a Kd of 1.6 μM. RSV604 displays submicromolar activity against numerous clinical isolates of both the A and B subtypes of RSV (average EC50s=0.8 μM).
    RSV604
  • HY-P99804
    Clesrovimab
    		Inhibitor 99.62%
    Clesrovimab (MK1654) is a fully human, anti-RSV fusion (RSV F) glycoprotein monoclonal antibody. Clesrovimab has the potential for the research of respiratory syncytial virus infection.
    Clesrovimab
  • HY-122587
    AVG-233
    		Inhibitor 98.87%
    AVG-233 is a potent, orally active RNA dependent RNA polymerase (RdRp) inhibitor. AVG-233 prevents initiation of the viral polymerase complex at the promoter. AVG-233 binding site is present in the L1-1749 fragment. AVG-233 has nanomolar activity against both RSV strains and clinical RSV isolates (EC50=0.14-0.31 μM). AVG-233 can be used for research of respiratory syncytial virus (RSV).
    AVG-233
  • HY-149648
    JNJ-8003
    		Inhibitor 99.84%
    JNJ-8003 is a potent inhibitor of RSV Polymerase. JNJ-8003 inhibits nucleotide polymerization of RNA transcription and replication at the early stages.
    JNJ-8003
  • HY-120632
    BMS-433771
    		Inhibitor 99.96%
    BMS-433771 is a potent orally active inhibitor of respiratory syncytial virus (RSV). BMS-433771 is active against both A and B groups of RSV, with an average EC50 of 20 nM. BMS-433771 can be used for the research of respiratory tract disease.
    BMS-433771
  • HY-P99586
    Suptavumab
    		Inhibitor
    Suptavumab (REGN2222) is a human monoclonal antibody. Suptavumab can bind and block a conserved epitope on RSV A and B subtypes. Suptavumab can be used for the research of RSV infection.
    Suptavumab
  • HY-147346
    Zelicapavir
    		Inhibitor 98.70%
    Zelicapavir (RSV-IN-7) (example 253) is a RSV inhibitor (EC50: < 0.4 μΜ).
    Zelicapavir
  • HY-11098
    JNJ 2408068
    		Inhibitor
    JNJ 2408068 is a potent RSV (respiratory syncytial virus) inhibitor. JNJ 2408068 significantly inhibits replication of RSV A and B subtypes in the lungs of cotton rats without any evidence of toxicity. The minimum protective dose of JNJ 2408068 appears to be approximately 0.39 mg/kg.
    JNJ 2408068
  • HY-123475A
    Sisunatovir hydrochloride
    		Inhibitor 98.61%
    Sisunatovir (RV521) hydrochloride, an orally available inhibitor of the RSV fusion (RSV-F) protein, exhibits potent efficacy against a panel of clinical isolates of RSV-A and RSV-B viruses, with IC50s of 1.4 nM and 1.0 nM, respectively.
    Sisunatovir hydrochloride
  • HY-W013605A
    4-Methoxycinnamaldehyde
    		Inhibitor 99.30%
    4-Methoxycinnamaldehyde (p-Methoxycinnamaldehyde), an active constituent of Agastache rugosa, exhibits cytoprotective activity against respiratory syncytial virus (RSV) in human larynx carcinoma cell line. 4-Methoxycinnamaldehyde effectively inhibits cytopathic effect of RSV with an estimated IC50 of 0.055 μg/mL.
    4-Methoxycinnamaldehyde
  • HY-12994
    VP-14637
    		Inhibitor ≥99.0%
    MDT-637 (VP 14637) is a novel respiratory syncytial virus (RSV) fusion inhibitor with an IC50 of 1.42 ng/mL.
    VP-14637
  • HY-109004
    Enzaplatovir
    		Inhibitor 99.98%
    Enzaplatovir (BTA-C585) is an orally bioavailable Inhibitor for respiratory syncytial virus (RSV) infection.
    Enzaplatovir
  • HY-126303
    GS-443902
    		Inhibitor 99.87%
    GS-443902 (GS-441524 triphosphate) is a potent viral RNA-dependent RNA-polymerases (RdRp) inhibitor with IC50s of 1.1 µM, 5 µM for RSV RdRp and HCV RdRp, respectively. GS-443902 is the active triphosphate metabolite of Remdesivir.
    GS-443902
  • HY-109004A
    (S)-Enzaplatovir
    		Inhibitor 99.35%
    (S)-Enzaplatovir ((S)-BTA-C585) is the S-enantiomer of Enzaplatovir. (S)-Enzaplatovir shows antiviral activities with an EC50 of 56 nM for respiratory syncytial viral (RSV) (patent WO2011094823A1 compound 77).
    (S)-Enzaplatovir
  • HY-12993A
    RSV604 racemate
    		Inhibitor 98.60%
    RSV604 (A-60444) racemate is a racemic mixture, shows less potency against strains of respiratory syncytial virus (RSV) than the S-isomer.
    RSV604 racemate
  • HY-N8448
    3,4-Di-O-caffeoyl quinic acid methyl ester
    		Inhibitor
    3,4-Di-O-caffeoyl quinic acid methyl ester (Macroantoin F) is a dicaffeoyl derivative isolated from the rhizome of Elephantopus scaber Linn. 3,4-Di-O-caffeoyl quinic acid methyl ester exhibited in vitro antiviral activity against respiratory syncytial virus (< a href=" " class="link-product" target="_blank">RSV) with an IC50 value of 0.78 μg/mL.
    3,4-Di-O-caffeoyl quinic acid methyl ester
  • HY-115574
    RSV L-protein-IN-1
    		Inhibitor
    RSV L-protein-IN-1 (compound D) is a potent inhibitor of Respiratory syncytial virus (RSV) (EC50=0.021 μM). RSV L-protein-IN-1 inhibits Polymerase (IC50=0.089 μM)，and blocks RSV mRNA synthesis by inhibiting guanylation of viral transcripts. RSV L-protein-IN-1 shows moderate cytotoxicity (CC50=8.4 μM，HEp-2)，also exhibits activity and lowers virus titers in mouse models of RSV infection.
    RSV L-protein-IN-1
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity